|
|
Post by dreamboatcruise on Oct 20, 2017 13:50:35 GMT -5
Any of the glucose monitor companies could co-promote for us/with us. "Buy a glucose monitor, get a month's supply of needle-free Afrezza" I think there is already a voucher for first month free for Afrezza... no need to buy a blood glucose monitor. |
|
|
|
Post by radgray68 on Oct 20, 2017 14:10:59 GMT -5
Any of the glucose monitor companies could co-promote for us/with us. "Buy a glucose monitor, get a month's supply of needle-free Afrezza" I think there is already a voucher for first month free for Afrezza... no need to buy a blood glucose monitor. Cool, so it costs us nothing more than we already give to co-promote. OR, How about this?: "Get a free glucose monitor with your first 90-day prescription of Afrezza." Perhaps we share the cost for the first million or so. |
|
|
|
Post by mnholdem on Oct 20, 2017 14:12:03 GMT -5
I'm not sure that CGM's would do that until they see the results from the OneDrop-MannKind A-One trial, scheduled with primary completion date of Feb 1, 2018. It's possible that those secondary outcomes are what may attract more collaborators among the CGM manufacturers. They may want to show that it's Afrezza, more than the OneDrop device, that resulted in higher patient satisfaction, adherence and quality of life. It's OneDrop that's the threat to their market share, not Afrezza.
Primary Outcome Hemoglobin A1c [ Time Frame: 3 months ] 3-month between-group change in A1c assessed by a central lab
Secondary Outcomes
Insulin Device Satisfaction [ Time Frame: 3 months ] Treatment Adherence [ Time Frame: 3 months ] Within- and between-group change in treatment adherence Self-care [ Time Frame: 3 months ] Within- and between-group change in self-care assessed by the SDSCA's other subscales Health-related Productivity [ Time Frame: 3 months ] Health-related Quality of Life [ Time Frame: 3 months ]
Source: clinicaltrials.gov/ct2/show/record/NCT03313960?term=onedrop&recrs=abdf&cond=Diabetes+Mellitus&rank=1
|
|
|
|
Post by dreamboatcruise on Oct 20, 2017 14:34:23 GMT -5
I'm not sure that CGM's would do that until they see the results from the OneDrop-MannKind A-One trial, scheduled with primary completion date of Feb 1, 2018. It's possible that those secondary outcomes are what may attract more collaborators among the CGM manufacturers. They may want to show that it's Afrezza, more than the OneDrop device, that resulted in higher patient satisfaction, adherence and quality of life. It's OneDrop that's the threat to their market share, not Afrezza.
Primary Outcome Hemoglobin A1c [ Time Frame: 3 months ] 3-month between-group change in A1c assessed by a central lab
Secondary Outcomes
Insulin Device Satisfaction [ Time Frame: 3 months ] Treatment Adherence [ Time Frame: 3 months ] Within- and between-group change in treatment adherence Self-care [ Time Frame: 3 months ] Within- and between-group change in self-care assessed by the SDSCA's other subscales Health-related Productivity [ Time Frame: 3 months ] Health-related Quality of Life [ Time Frame: 3 months ]
Source: clinicaltrials.gov/ct2/show/record/NCT03313960?term=onedrop&recrs=abdf&cond=Diabetes+Mellitus&rank=1
I see some logic with regard to having an underutilized sales team adding something that could be promoted to docs already being visited, but I don't see where an established CGM/meter company would see it as beneficial to take sides in insulin. As often happens, it can be easier for two new comers to strike a win-win deal that gets them both more attention (One Drop and Mannkind). Additionally, the synergy that I see with One Drop that wouldn't necessarily exist with other partners is that they have a coaching/education services component to their offering. We know that dosing/titration has been a problem for Afrezza in the past. Possibly it has gotten better, but I still imagine it is a barrier to get staff trained each time a new doctor is convinced to try prescribing Afrezza. One Drop is thus potentially a source to provide large, and scalable, patient facing support organization, who hopefully are getting all the latest and greatest advice about Afrezza use. |
|
|
|
Post by lennymnkd on Oct 20, 2017 15:01:39 GMT -5
|
|
|
|
Post by dreamboatcruise on Oct 20, 2017 15:21:50 GMT -5
I don't really see how an insulin makes a meter look good. That's a pretty superficial view. I don't think most patients would think a Dexcom meter is better than a Libre because they use Afrezza with it and get good results. You're mileage may vary as to how you'd interpret those results if using a meter. If anything, Afrezza probably makes meters (especially CGMs) less of a necessity. A CGM looks great when it beeps and saves your life in the middle of the night. If you don't have delayed hypos in the middle of the night, a CGM might be a nice to have, but less of a life saver, since it is primarily just saving you from needing to do frequent finger sticks. It's funny, I think I see some on here argue both sides of this... they'll say Afrezza is so great you can simply ballpark dose and get great results and then they'll simultaneously swear all the meter companies will feel they have to partner with Mannkind despite implying meters are less necessary with Afrezza. |
|
|
|
Post by lennymnkd on Oct 20, 2017 15:36:37 GMT -5
Can’t be too safe , why not the best of both worlds / this will be extremely attractive for those highly dedicated to their health in a intelligent manner ... and are willing to make the effort . Give me an example of why it would be a persons waste of time . With the synergies—the old saying a marriage made in heaven .
|
|
|
|
Post by mnholdem on Oct 20, 2017 15:49:44 GMT -5
I think most of us waffle a bit as we learn more because of our discussions. Gaining a broader perspective is one of the things I value most about ProBoards-MNKD. OneDrop is not married to MannKind. They are also collaborating with Sanofi on a study, according to a recent press release. Likewise, these CGM companies don't need to take a one-or-none approach with working with BP. They're free to set up any number of agreements. The big question is whether all the BPs who market insulin would want real-time data. Not all RAA insulin brands are the same and they've done a masterful job of hiding their deficiencies for many years.  |
|
|
|
Post by akemp3000 on Oct 20, 2017 16:04:32 GMT -5
Yes mnholdem! The entire diabetes industry has done a masterful job of hiding deficiencies and inadequate results for decades. With CGMs and new studies coming, they are about to be exposed. The paradigm shift is really just starting. Afrezza is sitting in a most enviable position being the only solution that closely mimics a healthy pancreas. This has to be known by the giant BP players and should make the coming year very interesting to say the least.
|
|
|
|
Post by lennymnkd on Oct 20, 2017 16:22:21 GMT -5
That’s why Matt AND AL had said on numerous occasions we are a technology company , the day they have been waiting for is almost here/ almost here for the naysayers.... and have to admit the day this six yr long loyal investor has been waiting for. This will change the diabetes dynamics .
|
|
|
|
Post by letitride on Oct 20, 2017 16:38:46 GMT -5
Instant gratification is the #1 reason Afrezza is the perfect compliment to a CGM. This is what people want not to wait 3 months to find out how their doing. No other insulin on the market is going to show them its working in real time like Afrezza will.
|
|
|
|
Post by sellhighdrinklow on Oct 20, 2017 17:36:27 GMT -5
Can’t be too safe , why not the best of both worlds / this will be extremely attractive for those highly dedicated to their health in a intelligent manner ... and are willing to make the effort . Give me an example of why it would be a persons waste of time . With the synergies—the old saying a marriage made in heaven . You are 100% correct, imho |
|
|
|
Post by joeypotsandpans on Oct 20, 2017 17:45:49 GMT -5
I think most of us waffle a bit as we learn more because of our discussions. Gaining a broader perspective is one of the things I value most about ProBoards-MNKD. OneDrop is not married to MannKind. They are also collaborating with Sanofi on a study, according to a recent press release. Likewise, these CGM companies don't need to take a one-or-none approach with working with BP. They're free to set up any number of agreements. The big question is whether all the BPs who market insulin would want real-time data. Not all RAA insulin brands are the same and they've done a masterful job of hiding their deficiencies for many years while throwing a big blanket over the 800lb gorilla in the room. MN I had to edit this and take the rest of the words out of your mouth (I was being kind with how you put it also), somehow you got cutoff  |
|
|
|
Post by mnholdem on Oct 20, 2017 17:49:40 GMT -5
The fact that the OneDrop-MannKind A-ONE trial has reduction of a1C as the only primary outcome serves to remind us that the industry still revolves around that antiquated measurement. This outcome is critical to demonstrate to health care professionals that Afrezza is superior to the current RAA insulin treatments being compared in the other arm. In time, the Secondary Outcomes will become valuable, especially those related to adherence and quality of life. I mentioned in another thread that I thought Apple became successful because Steve Jobs targeted lifestyle for his direct to consumers marketing campaign. MannKind has already provided us with a glimpse of something very similar in cable-TV ad they aired during the Charles Mattocks reality program "Reversed". Life is full of unexpected surprises. Afrezza can help you manage the unexpected. That's a lifestyle message and people with diabetes will certainly relate to, IMO.  |
|
|
|
Post by dreamboatcruise on Oct 20, 2017 18:22:38 GMT -5
Instant gratification is the #1 reason Afrezza is the perfect compliment to a CGM. This is what people want not to wait 3 months to find out how their doing. No other insulin on the market is going to show them its working in real time like Afrezza will. Yet you might be surprised at how many, especially T2 patients, actually prefer thinking as little as possible about diabetes, hence why so many have poor compliance/control. It might be easy to imagine that "instant gratification" is something people always want, but thinking that most people would derive instant gratification from knowing their BG all the time might be stretching things. Perhaps you should ask some people with diabetes if 24/7 monitoring of their BG is something from which they would derive that sort of enjoyment. I think following MNKD, especially through proboards, it's easy to start thinking that Sam and the other frequent social media Afrezza advocates are the typical patient with diabetes... when they really aren't. |
|
